Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma

Ping I. Hsu, Nan-Haw Chow, Kwok Hung Lai, Hsiao Bai Yang, Shih-Huang Chan, Xi-Zhang Lin, Jin Shiung Cheng, Jia Sheng Huang, Luo Ping Ger, Shih-Ming Huang, Muh Yong Yen, Yun Fu Yang

研究成果: Article

40 引文 (Scopus)

摘要

Angiogenesis occurs in response to tissue damage, and is of vital importance for tumor growth and metastasis. Basic fibroblast growth factor (bFGF), a well-known angiogenic factor, has been suggested to be a useful diagnostic marker in certain hypervascular tumors. However, the relevance of its detection has not been well evaluated in patients with hepatocelluar carcinoma (HCC) and benign chronic liver diseases. In the current study, immunoassay of bFGF was performed on serum samples from 39 patients with HCC, 21 with liver cirrhosis, 22 with chronic hepatitis and 40 normal subjects. The serum bFGF level was significantly increased in patients with liver cirrhosis and HCC when compared with those with chronic hepatitis or normal subjects (all p-values < 0.001). However, no difference was observed between the groups with liver cirrhosis and HCC (p > 0.05). If we set 9.6 pg/ml (mean + 3 standard deviations of bFGF in the control group) as the upper limit of normal serum level of bFGF, elevated bFGF concentrations were noted in 9.1%, 42.9% and 51.3% of patients with chronic hepatitis, liver cirrhosis and HCC respectively. In non-cancer patients the coexistence of acute illness (p = 0.000) was an independent factor related to the elevation of serum bFGF. On the other hand, a multivariate analysis demonstrated that both advanced stage of cancer (p = 0.026) and coexistence of acute illness (p = 0.000) influence the serum level of bFGF in patients with HCC. We conclude that serum bFGF levels are significantly higher in patients with HCC and are positively correlated with advanced tumor stage. Nevertheless, elevation of serum bFGF may also be observed in a significant number of patients with liver cirrhosis. Therefore, measurement of serum bFGF alone cannot be satisfactory as a tumor marker for diagnosis of HCC. In addition, it is important to point out that coexistence of acute illness may be a crucial confounding factor in the diagnosis or monitoring of any cancer by the estimation of selum bFGF.

原文English
頁(從 - 到)2803-2809
頁數7
期刊Anticancer Research
17
發行號4 A
出版狀態Published - 1997 九月 3

指紋

Fibroblast Growth Factor 2
Liver Diseases
Hepatocellular Carcinoma
Chronic Disease
Serum
Carcinoma
Liver Cirrhosis
Chronic Hepatitis
Neoplasms
Angiogenesis Inducing Agents
Tumor Biomarkers
Immunoassay
Multivariate Analysis
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

引用此文

Hsu, Ping I. ; Chow, Nan-Haw ; Lai, Kwok Hung ; Yang, Hsiao Bai ; Chan, Shih-Huang ; Lin, Xi-Zhang ; Cheng, Jin Shiung ; Huang, Jia Sheng ; Ger, Luo Ping ; Huang, Shih-Ming ; Yen, Muh Yong ; Yang, Yun Fu. / Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. 於: Anticancer Research. 1997 ; 卷 17, 編號 4 A. 頁 2803-2809.
@article{bb24b7b60f5845b8b7c9174c48e83883,
title = "Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma",
abstract = "Angiogenesis occurs in response to tissue damage, and is of vital importance for tumor growth and metastasis. Basic fibroblast growth factor (bFGF), a well-known angiogenic factor, has been suggested to be a useful diagnostic marker in certain hypervascular tumors. However, the relevance of its detection has not been well evaluated in patients with hepatocelluar carcinoma (HCC) and benign chronic liver diseases. In the current study, immunoassay of bFGF was performed on serum samples from 39 patients with HCC, 21 with liver cirrhosis, 22 with chronic hepatitis and 40 normal subjects. The serum bFGF level was significantly increased in patients with liver cirrhosis and HCC when compared with those with chronic hepatitis or normal subjects (all p-values < 0.001). However, no difference was observed between the groups with liver cirrhosis and HCC (p > 0.05). If we set 9.6 pg/ml (mean + 3 standard deviations of bFGF in the control group) as the upper limit of normal serum level of bFGF, elevated bFGF concentrations were noted in 9.1{\%}, 42.9{\%} and 51.3{\%} of patients with chronic hepatitis, liver cirrhosis and HCC respectively. In non-cancer patients the coexistence of acute illness (p = 0.000) was an independent factor related to the elevation of serum bFGF. On the other hand, a multivariate analysis demonstrated that both advanced stage of cancer (p = 0.026) and coexistence of acute illness (p = 0.000) influence the serum level of bFGF in patients with HCC. We conclude that serum bFGF levels are significantly higher in patients with HCC and are positively correlated with advanced tumor stage. Nevertheless, elevation of serum bFGF may also be observed in a significant number of patients with liver cirrhosis. Therefore, measurement of serum bFGF alone cannot be satisfactory as a tumor marker for diagnosis of HCC. In addition, it is important to point out that coexistence of acute illness may be a crucial confounding factor in the diagnosis or monitoring of any cancer by the estimation of selum bFGF.",
author = "Hsu, {Ping I.} and Nan-Haw Chow and Lai, {Kwok Hung} and Yang, {Hsiao Bai} and Shih-Huang Chan and Xi-Zhang Lin and Cheng, {Jin Shiung} and Huang, {Jia Sheng} and Ger, {Luo Ping} and Shih-Ming Huang and Yen, {Muh Yong} and Yang, {Yun Fu}",
year = "1997",
month = "9",
day = "3",
language = "English",
volume = "17",
pages = "2803--2809",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 A",

}

Hsu, PI, Chow, N-H, Lai, KH, Yang, HB, Chan, S-H, Lin, X-Z, Cheng, JS, Huang, JS, Ger, LP, Huang, S-M, Yen, MY & Yang, YF 1997, 'Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma', Anticancer Research, 卷 17, 編號 4 A, 頁 2803-2809.

Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma. / Hsu, Ping I.; Chow, Nan-Haw; Lai, Kwok Hung; Yang, Hsiao Bai; Chan, Shih-Huang; Lin, Xi-Zhang; Cheng, Jin Shiung; Huang, Jia Sheng; Ger, Luo Ping; Huang, Shih-Ming; Yen, Muh Yong; Yang, Yun Fu.

於: Anticancer Research, 卷 17, 編號 4 A, 03.09.1997, p. 2803-2809.

研究成果: Article

TY - JOUR

T1 - Implications of serum basic fibroblast growth factor levels in chronic liver diseases and hepatocellular carcinoma

AU - Hsu, Ping I.

AU - Chow, Nan-Haw

AU - Lai, Kwok Hung

AU - Yang, Hsiao Bai

AU - Chan, Shih-Huang

AU - Lin, Xi-Zhang

AU - Cheng, Jin Shiung

AU - Huang, Jia Sheng

AU - Ger, Luo Ping

AU - Huang, Shih-Ming

AU - Yen, Muh Yong

AU - Yang, Yun Fu

PY - 1997/9/3

Y1 - 1997/9/3

N2 - Angiogenesis occurs in response to tissue damage, and is of vital importance for tumor growth and metastasis. Basic fibroblast growth factor (bFGF), a well-known angiogenic factor, has been suggested to be a useful diagnostic marker in certain hypervascular tumors. However, the relevance of its detection has not been well evaluated in patients with hepatocelluar carcinoma (HCC) and benign chronic liver diseases. In the current study, immunoassay of bFGF was performed on serum samples from 39 patients with HCC, 21 with liver cirrhosis, 22 with chronic hepatitis and 40 normal subjects. The serum bFGF level was significantly increased in patients with liver cirrhosis and HCC when compared with those with chronic hepatitis or normal subjects (all p-values < 0.001). However, no difference was observed between the groups with liver cirrhosis and HCC (p > 0.05). If we set 9.6 pg/ml (mean + 3 standard deviations of bFGF in the control group) as the upper limit of normal serum level of bFGF, elevated bFGF concentrations were noted in 9.1%, 42.9% and 51.3% of patients with chronic hepatitis, liver cirrhosis and HCC respectively. In non-cancer patients the coexistence of acute illness (p = 0.000) was an independent factor related to the elevation of serum bFGF. On the other hand, a multivariate analysis demonstrated that both advanced stage of cancer (p = 0.026) and coexistence of acute illness (p = 0.000) influence the serum level of bFGF in patients with HCC. We conclude that serum bFGF levels are significantly higher in patients with HCC and are positively correlated with advanced tumor stage. Nevertheless, elevation of serum bFGF may also be observed in a significant number of patients with liver cirrhosis. Therefore, measurement of serum bFGF alone cannot be satisfactory as a tumor marker for diagnosis of HCC. In addition, it is important to point out that coexistence of acute illness may be a crucial confounding factor in the diagnosis or monitoring of any cancer by the estimation of selum bFGF.

AB - Angiogenesis occurs in response to tissue damage, and is of vital importance for tumor growth and metastasis. Basic fibroblast growth factor (bFGF), a well-known angiogenic factor, has been suggested to be a useful diagnostic marker in certain hypervascular tumors. However, the relevance of its detection has not been well evaluated in patients with hepatocelluar carcinoma (HCC) and benign chronic liver diseases. In the current study, immunoassay of bFGF was performed on serum samples from 39 patients with HCC, 21 with liver cirrhosis, 22 with chronic hepatitis and 40 normal subjects. The serum bFGF level was significantly increased in patients with liver cirrhosis and HCC when compared with those with chronic hepatitis or normal subjects (all p-values < 0.001). However, no difference was observed between the groups with liver cirrhosis and HCC (p > 0.05). If we set 9.6 pg/ml (mean + 3 standard deviations of bFGF in the control group) as the upper limit of normal serum level of bFGF, elevated bFGF concentrations were noted in 9.1%, 42.9% and 51.3% of patients with chronic hepatitis, liver cirrhosis and HCC respectively. In non-cancer patients the coexistence of acute illness (p = 0.000) was an independent factor related to the elevation of serum bFGF. On the other hand, a multivariate analysis demonstrated that both advanced stage of cancer (p = 0.026) and coexistence of acute illness (p = 0.000) influence the serum level of bFGF in patients with HCC. We conclude that serum bFGF levels are significantly higher in patients with HCC and are positively correlated with advanced tumor stage. Nevertheless, elevation of serum bFGF may also be observed in a significant number of patients with liver cirrhosis. Therefore, measurement of serum bFGF alone cannot be satisfactory as a tumor marker for diagnosis of HCC. In addition, it is important to point out that coexistence of acute illness may be a crucial confounding factor in the diagnosis or monitoring of any cancer by the estimation of selum bFGF.

UR - http://www.scopus.com/inward/record.url?scp=0030792419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030792419&partnerID=8YFLogxK

M3 - Article

C2 - 9252719

AN - SCOPUS:0030792419

VL - 17

SP - 2803

EP - 2809

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 A

ER -